Clinical Trial

The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression

Study acronym: esketamine
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The aim of this study is to observe the antidepressant effect of low-dose esketamine in obese patients with preoperative depression and seeking bariatric surgery. We speculate that intraoperative infusion and the addition of a small dose of esketamine to the postoperative analgesic pump can help reduce the proportion of patients with depression after surgery, and may further improve postoperative recovery, reduce the use of postoperative opioids, shorten postoperative hospital stay, and improve postoperative quality of life of patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-11.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-05-06
Trial Details
NCT Number NCT07179913
Lead Sponsor The First Hospital of Jilin University
Conditions Depressed, Bariatric Surgery
Enrollment 40 participants
Start Date 2026-05-01
Primary Completion 2026-11-20 (estimated)
Study Completion 2026-11-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-08